Orphazyme gets requested observation status

Nasdaq Copenhagen has listened to Orphazyme’s plea to be placed under observation, which the company requested at around the same time it asked for court protection to restructure.

Photo: Orphazyme/PR

On Friday, biotech firm Oprhazyme has been moved to Nasdaq Copenhagen’s observation list.

The request came shortly after Oprhazyme sought protection from creditors, which would allow time for an in-court restructuring of the company, Nasdaq reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs